HIKAL Annual Report is a must read for everyone tracking the CDMO/API/Intermediates industry.
HIKAL being a hybrid player, their Annual Report insights on Pharma, Animal Health and Crop
More from Saket Reddy
SAREGAMA
Today's closing is a monthly close and this is done & dusted, we now have a solid monthly close above the 10 year supply zone.
If the stock has broken out from a 10 year supply zone & a 20 year peak, surely something would've changed!
Do study the industry structure! https://t.co/zA3qztFzon
Today's closing is a monthly close and this is done & dusted, we now have a solid monthly close above the 10 year supply zone.
If the stock has broken out from a 10 year supply zone & a 20 year peak, surely something would've changed!
Do study the industry structure! https://t.co/zA3qztFzon
SAREGAMA at a very important juncture now on the monthly chart considering today's close is also a monthly close.
— Saket Reddy (@saketreddy) May 31, 2021
Nearing a breakout from over a 10 year supply zone! https://t.co/qpsSn3obrE pic.twitter.com/1xTmB6WvhK
More from Hikal
Key insights from Hikal
🧪 Lowered interest rates
🧪 Pharma: Growth in generics as well as CDMO
🧪 Crop Protection: Scaleup of a fungicide for a Japanese CDMO client
🧪 Healthy pipeline of new products: Supported by new capacities; Investing in Animal Health & Biocides verticals https://t.co/D70j9oriCa
🧪 Lowered interest rates
🧪 Pharma: Growth in generics as well as CDMO
🧪 Crop Protection: Scaleup of a fungicide for a Japanese CDMO client
🧪 Healthy pipeline of new products: Supported by new capacities; Investing in Animal Health & Biocides verticals https://t.co/D70j9oriCa
Hikal: Strong
— JST Investments (@JstInvestments) August 5, 2021
\U0001f9ea Rev up 27% YoY
\U0001f9ea 22% EBITDA margin
\U0001f9ea Pat of 50crs
\U0001f9ea Growth across both pharmaceuticals & crop protection.#Q1withJST #Pharma pic.twitter.com/8lFo68KzPe